Drug Trial Radar · NCT05396105
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
150
Planned (sponsor's estimate)
Start
Dec 28, 2022
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Pharvaris Netherlands B.V.Industry
- Sponsor type
- Industry
- First posted
- May 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the safety and efficacy of long-term on-demand treatment with orally administered deucrictibant for acute hereditary angioedema (HAE) attacks, including laryngeal attacks. The study will enroll participants from Study PHA022121-C201 (NCT04618211), Study PHA022121-C306 (NCT06343779) and deucrictibant treatment naïve HAE-nC1INH adult participants who elect to participate in this extension study and meet the eligibility requirements.
Conditions
- Hereditary Angioedema
- Hereditary Angioedema Type I
- Hereditary Angioedema Type II
- Hereditary Angioedema Types I and II
- Hereditary Angioedema Attack
- Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
- Hereditary Angioedema - Type 1
- Hereditary Angioedema - Type 2
- Hereditary Angioedema - Type 3
- C1 Esterase Inhibitor [C1-INH] Deficiency
- C1 Esterase Inhibitor Deficiency
- C1 Esterase Inhibitor, Deficiency of
- C1 Inhibitor Deficiency
- Hereditary Angioedema Type III
- Hereditary Angioedema (HAE)
- Hereditary Angioedema Type I and II
- HAE With Normal C1 Esterase Inhibitor
Interventions
deucrictibantDrug
3 capsules of deucrictibant or matching placebo will be administered orally for each HAE attack
deucrictibantDrug
deucrictibant soft capsules will be administered orally for each HAE attack
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent Adverse Events (TEAEs), treatment-related TEAEs, treatment-emergent serious adverse events (TESAEs), treatment-related TESAEs, and TEAEs leading to deucrictibant discontinuationTime frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
- Heart RateTime frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
- Blood pressureTime frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
- Body temperatureTime frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
- Clinical laboratory testsTime frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
- ElectrocardiogramsTime frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
- Physical ExaminationTime frame: From enrollment through study completion, up to 54 months (dependent on time of enrollment).
Locations
60 sites in 24 countries. Site status is shown where the registry gives one.
Study site
Birmingham, Alabama
Study site
Little Rock, Arkansas
Study site
San Diego, California
Study site
Santa Monica, California
Study site
Walnut Creek, California
Study site
Colorado Springs, Colorado
Study site
Chevy Chase, Maryland
Study site
Boston, Massachusetts
Study site
Detroit, Michigan
Study site
St Louis, Missouri
Study site
Hershey, Pennsylvania
Study site
Dallas, Texas
Study site
Buenos Aires, Argentina
Study site
Salta, Argentina
Study site
Campbelltown, New South Wales, Australia
Study site
Graz, Austria
Study site
Vienna, Austria
Study site
Ribeirão Preto, Brazil
Study site
Santo André, Brazil
Study site
São Paulo, Brazil
Study site
Salvador, Estado de Bahia, Brazil
Study site
Sofia, Bulgaria
Study site
Sofia, Bulgaria
Study site
Edmonton, Alberta, Canada
Study site
Montreal, Quebec, Canada
Study site
Brno, Czechia
Study site
Grenoble, France
Study site
Paris, France
Study site
Berlin, Germany
Study site
Frankfurt am Main, Germany
Study site
Frankfurt am Main, Germany
Study site
Lübeck, Germany
Study site
Hong Kong, Hong Kong
Study site
Budapest, Hungary
Study site
Ashkelon, Israel
Study site
Catania, Italy
Study site
Milan, Italy
Study site
Milan, Italy
Study site
Naples, Italy
Study site
Padova, Italy
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.